Athira Pharma, Inc. — Director's Dealing 2025

Mar 12, 2025

SEC Form 4/A — Form 4/A

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2025-03-03

Reporting Person: Renninger Robert (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-03	Stock Option (Right to Buy)	$0.3762	A	73350	Acquired	2035-03-02	Common Stock (73350)	Direct

Footnotes

F1: One fourth (1/4th) of shares subject to the option shall be scheduled to vest on the one (1)-year anniversary of the grant date, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option each month thereafter on the same day of the month as the grant date subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.